UPDATE: The Australian Therapeutic Goods Administration (TGA) has just approved the revolutionary software device, Claritas iPET™, for medical use in Australia. This groundbreaking technology promises to enhance diagnostic imaging quality from Positron Emission Tomography (PET) scans, significantly improving patient care and experience.
This approval, announced on March 06, 2026, marks a crucial expansion for Claritas NucMed Technologies Ltd, a leader in healthcare technology based in London and Sydney. The approval allows Claritas iPET™ to be integrated into hospital systems across Australia, facilitating enhanced imaging capabilities that are agnostic to equipment type and manufacturer.
Why this matters NOW: As healthcare providers face increasing pressures to improve diagnostic accuracy while minimizing radiation exposure, Claritas iPET™ offers a timely solution. The software enhances noisy PET scans to yield clearer, sharper images, enabling healthcare professionals to detect fine lesions without compromising on data integrity. This technology is essential in a landscape where every second and every dose counts in medical imaging.
Dr. Fernando Salis, a nuclear medicine physician and director of Claritas NucMed Brazil, emphasized the growing demand for iPET™ in Brazil, stating that hospitals utilizing the software have significantly increased their patient throughput. “We are extremely pleased to see the response and demand in Brazil where hospitals have implemented Claritas iPET™ to improve the quality and efficiency of PET scans,” he noted, highlighting the software’s role in enhancing patient access and reducing costs.
The features of Claritas iPET™ allow for reduced scan times and lower isotope dosages, which not only increases the number of scans conducted daily but also enhances the overall patient experience. By integrating CT or MRI data as overlays, the software provides additional clarity, fostering more accurate diagnoses.
As hospitals and clinics prepare to implement this innovative technology, the potential for improved diagnostics and increased patient safety is clear. Claritas aims to transform the diagnostics industry through advanced image enhancement and AI technologies, ensuring that healthcare providers can make timely and accurate decisions.
With this recent approval, watch for rapid adoption in medical facilities across Australia. The impact on patient care could be profound, as healthcare professionals gain access to this essential tool that prioritizes both efficiency and safety.
For more information about Claritas and its suite of medical imaging products, visit www.claritashealthtech.com.
Stay tuned for further updates as Claritas iPET™ begins to reshape the landscape of medical imaging in Australia and beyond.
